



## Evofem Biosciences to Participate in Stifel 2021 Virtual Healthcare Conference

SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Sandra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows:

---

Date	Tuesday, November 16, 2021
Time	1:20 p.m. ET
Format	Fireside Chat
Room	Track 2
Webcast (live and replay)	<a href="https://wsw.com/webcast/stifel58/evfm/2096280">https://wsw.com/webcast/stifel58/evfm/2096280</a>

The webcast will be archived in the Events and Presentations section of the Company's website at <https://evofem.investorroom.com/Stifel2021>.

Additionally, Evofem Biosciences will host one-on-one meetings on Tuesday, November 16, 2021. Meetings can be requested exclusively via Stifel.

### About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes

before each act of sex. Learn more at [phexxi.com](http://phexxi.com) and [evofem.com](http://evofem.com).

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

## Investor Relations Contact

Amy Raskopf

Evofem Biosciences, Inc.

[araskopf@evofem.com](mailto:araskopf@evofem.com)

Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.